Yidu Tech, Inc. (2158) AI Stock Analysis

• Market Cap: HK$5.97B
• Dividend Yield: N/A
• Average Volume (3M): 6.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: -4.99%
• EPS Growth: 47.18%
• Country: HK
• Employees: 866
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 1,072,650,600
• 10 Day Avg. Volume: 6,345,530
• 30 Day Avg. Volume: 6,499,248
• PEG Ratio: 1.23
• Price to Book (P/B): 1.55
• Price to Sales (P/S): 8.53
• P/FCF Ratio: -17.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$11.00
• Price Target Upside: 97.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.03
• Revenue Forecast (FY): HK$777.12M

• Rating: 45 Neutral
• Price Target: HK$5.50 ▼(-1.43% Downside)
• Action: Upgraded Date: 01/13/26
• Date: Action: Upgraded 01/13/26

The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and negative operating cash flow), partially offset by a stable, low-leverage balance sheet. Technicals show strong recent momentum with the stock trading above major moving averages, but overbought signals raise near-term risk. Valuation remains unattractive/unclear due to negative earnings (negative P/E) and no indicated dividend yield.

Positive Factors

Conservative balance sheet (low leverage)

A very low debt-to-equity ratio and high equity ratio provide durable financial flexibility, lowering solvency risk and reducing refinancing pressure. This conservative capital structure supports continued R&D and partnership investments over months, giving management time to fix operating issues without immediate liquidity strain.

Improving free cash flow generation

An increase in free cash flow growth and a positive FCF-to-net-income ratio indicate the company can generate cash despite accounting losses. Durable FCF improvement provides a pathway to self-fund product development and support customers, reducing dependence on external funding if trends persist over the next several quarters.

Recurring subscription and partnership revenue model

A subscription-based SaaS model plus licensing and strategic partnerships creates recurring revenue, customer stickiness and predictable renewal streams. This structural revenue mix supports steady unit economics and upsell opportunities, which are durable advantages for revenue visibility and long-term client relationships in healthcare.

Negative Factors

Declining revenue growth

Sustained revenue contraction undermines scale economics and erodes pricing power in core healthcare software markets. Over a 2–6 month horizon, continued negative top-line trends threaten R&D funding, partner confidence and the ability to invest in sales expansion, making recovery of margins and market share more difficult.

Negative operating cash flow

Persistent negative operating cash flow signals that core operations are not converting revenue into cash, creating ongoing liquidity pressure. This structural shortfall forces reliance on financing or asset sales to cover working capital, constraining long-term investments and weakening resilience against market or execution setbacks.

Ongoing losses and negative return on equity

Negative ROE and recurring losses indicate the company is not delivering returns on shareholder capital, which can limit access to equity funding and impair long-term investor support. Without sustained margin recovery or revenue stabilization, the equity base may not generate acceptable returns over the medium term.

Yidu Tech, Inc. Business Overview & Revenue Model

Company Description

Yidu Tech, Inc. is a leading healthcare technology company based in China, specializing in providing data-driven solutions for the healthcare sector. The company integrates artificial intelligence and big data analytics to enhance the efficiency and quality of healthcare delivery. Yidu Tech's core products include medical data platforms, AI-driven diagnostic tools, and healthcare management systems, which cater to hospitals, healthcare providers, and pharmaceutical companies.

How the Company Makes Money

Yidu Tech generates revenue primarily through its subscription-based model for its data platforms and healthcare management systems, charging healthcare institutions for access and usage. Additionally, the company earns revenue from licensing its AI diagnostic tools and analytics software to hospitals and clinics. Strategic partnerships with healthcare providers and pharmaceutical companies also contribute to its earnings, as these collaborations often lead to joint projects and shared revenue opportunities. Furthermore, Yidu Tech's involvement in research and development projects funded by governmental and private organizations helps bolster its financial standing.

Yidu Tech, Inc. Financial Statement Overview

Summary

Financials are pressured by declining revenue growth (-8.34%) and negative profitability (net profit and EBIT margins). The balance sheet is conservatively financed (debt-to-equity 0.03; equity ratio ~83.6%), but negative ROE and negative operating cash flow indicate ongoing operational strain despite improved free cash flow.

Income Statement

Yidu Tech, Inc. has experienced declining revenue growth, with a negative growth rate of -8.34% in the most recent year. The company also faces challenges in profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased from the previous year, indicating pressure on cost management. Overall, the income statement reflects a need for improvement in revenue generation and cost control.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.03, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio remains strong at approximately 83.6%, suggesting a solid equity base relative to total assets. Despite the low leverage, the company needs to improve profitability to enhance shareholder returns.

Cash Flow

Yidu Tech, Inc. has shown a significant increase in free cash flow growth, but the operating cash flow remains negative, indicating operational challenges. The free cash flow to net income ratio is positive, suggesting that the company is generating cash relative to its net losses. However, the negative operating cash flow to net income ratio highlights the need for better cash flow management.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2021
Income Statement
Total Revenue	741.32M	714.98M	807.08M	804.70M	1.24B	867.04M
Gross Profit	254.99M	239.18M	339.44M	274.50M	396.89M	327.34M
EBITDA	-242.43M	-89.62M	-170.77M	-579.98M	-715.70M	-3.65B
Net Income	-88.85M	-117.79M	-194.94M	-627.97M	-762.32M	-3.70B
Balance Sheet
Total Assets	4.66B	4.69B	4.82B	4.91B	4.72B	5.25B
Cash, Cash Equivalents and Short-Term Investments	2.26B	3.30B	3.70B	3.75B	3.77B	4.63B
Total Debt	130.73M	129.54M	95.20M	14.13M	52.16M	26.43M
Total Liabilities	719.74M	711.37M	732.21M	755.36M	715.34M	497.71M
Stockholders Equity	3.88B	3.92B	4.02B	4.08B	3.99B	4.73B
Cash Flow
Free Cash Flow	-213.83M	-350.78M	-367.20M	-374.60M	-672.14M	-350.73M
Operating Cash Flow	-110.32M	-248.81M	-326.38M	-357.01M	-614.68M	-331.68M
Investing Cash Flow	554.47M	116.71M	466.90M	-2.34B	3.39B	-3.87B
Financing Cash Flow	67.23M	20.04M	82.21M	361.45M	-35.23M	4.26B

Yidu Tech, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2158, the sentiment is Negative. The current price of 5.58 is below the 20-day moving average (MA) of 5.84, below the 50-day MA of 5.81, and below the 200-day MA of 5.90, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.55 is Neutral, neither overbought nor oversold. The STOCH value of 18.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2158.

Yidu Tech, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1763	74 Outperform	HK$6.69B	6.29	8.59%	2.76%	13.59%	6.31%
2877	73 Outperform	HK$6.90B	2.21	10.85%	5.80%	-20.64%	-25.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2159	47 Neutral	HK$425.60M	-6.27	-35.99%	―	-5.38%	63.93%
2158	45 Neutral	HK$5.97B	-110.24	-2.23%	―	-4.99%	47.18%
2616	42 Neutral	HK$9.10B	-9.27	-95.84%	―	-55.64%	-158.67%
2251	40 Neutral	HK$1.13B	-176.64	-12.97%	―	-32.17%	-1.20%

Yidu Tech, Inc. Corporate Events

Yidu Tech executive director Dr. Xie Li to step down in February 2026

Yidu Tech Inc. has announced that executive director Dr. Xie Li will resign from the board with effect from 13 February 2026 to focus on personal matters, according to a company statement. Dr. Xie has indicated she has no disagreement with the board and that there are no issues related to her departure requiring attention from shareholders or the Hong Kong stock exchange.

The board expressed gratitude for Dr. Xie’s contributions during her tenure, while confirming the remaining composition of executive, non-executive and independent non-executive directors. The orderly and amicable nature of the transition suggests limited immediate disruption to corporate governance, though investors may watch for any subsequent appointments or strategic shifts following the change in leadership.

The most recent analyst rating on (HK:2158) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Yidu Tech, Inc. stock, see the HK:2158 Stock Forecast page.

Yidu Tech Reshapes Board and Committee Roles to Bolster Governance

Yidu Tech Inc. has updated its board composition effective 13 February 2026, confirming a three-tier structure of executive, non-executive and independent non-executive directors led by Chairlady Gong Yingying and CEO Xu Jiming. The board also includes non-executive director Zeng Ming and independent non-executive directors Ma Wei-Ying, Pan Rongrong and Zhang Linqi, reinforcing a mix of management, strategic and oversight expertise.

The company maintains three key board committees for audit, remuneration and nomination, with independent directors occupying most chair roles to strengthen governance. Dr. Ma Wei-Ying chairs the audit committee, Pan Rongrong leads the remuneration committee and Gong Yingying heads the nomination committee, signaling an emphasis on robust oversight and balanced decision-making as the company advances its strategic objectives.

The most recent analyst rating on (HK:2158) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Yidu Tech, Inc. stock, see the HK:2158 Stock Forecast page.

Yidu Tech Confirms Qualification of Joint Company Secretary and Retains Dual Role for Governance

Yidu Tech Inc. announced that the Hong Kong Stock Exchange has confirmed joint company secretary Ms. Feng Xiaoying now fully meets the qualifications required under the Listing Rules to serve as company secretary. Despite this, the company will retain Hong Kong-based Ms. Li Ching Yi as joint company secretary to uphold high standards of corporate governance and to ensure efficient compliance with applicable laws and regulations, signalling a continued emphasis on robust administrative oversight and regulatory adherence.

The most recent analyst rating on (HK:2158) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Yidu Tech, Inc. stock, see the HK:2158 Stock Forecast page.